Key facts
- This page summarizes Stonepine Capital Management, LLC's Form 3 filing for Quoin Pharmaceuticals, Ltd. (QNRX).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 02 Feb 2026, 20:00.
Stonepine Capital Management, LLC - 29 Jan 2026 Form 3 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- QNRX
- Reported as of
- 29 Jan 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 02 Feb 2026, 20:00:50 UTC
- Prior SEC filing
- 14 May 2021
- Next SEC filing
- 31 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jon M. Plexico, Managing Mermber of Stonepine Capital Management, LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stonepine Capital Management, LLC filed Form 3 for Quoin Pharmaceuticals, Ltd. (QNRX) on 02 Feb 2026.
Change
- Previous filing in this sequence was filed on 14 May 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001440771
Primary reporting owner
Stonepine Capital Management, LLC
- Relationship
- 10%+ Owner
- Address
- 2900 NW CLEARWATER DRIVE, SUITE 100-11, BEND
- Signature
- /s/ Jon M. Plexico, Managing Mermber of Stonepine Capital Management, LLC
- Signature date
- 02 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
QNRX
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,271,100
- Date
- 29 Jan 2026
- Ownership
- See Note
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
QNRX
holding
Derivative
Pre-Funded Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Jan 2026
- Ownership
- See Note 2
- Underlying class
- ADS
- Underlying amount
- 81,212
- Exercise price
- $0.000100
- Footnotes
- F3, F4
QNRX
holding
Derivative
Series H Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Jan 2026
- Ownership
- See Note 2
- Underlying class
- ADS
- Underlying amount
- 121,212
- Exercise price
- $9.08
- Footnotes
- F4, F5
QNRX
holding
Derivative
Series I Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Jan 2026
- Ownership
- See Note 2
- Underlying class
- ADS
- Underlying amount
- 121,212
- Exercise price
- $10.31
- Footnotes
- F4, F6
QNRX
holding
Derivative
Series J Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Jan 2026
- Ownership
- See Note 2
- Underlying class
- ADS
- Underlying amount
- 121,212
- Exercise price
- $12.38
- Footnotes
- F4, F7
QNRX
holding
Derivative
Series K Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Jan 2026
- Ownership
- See Note 2
- Underlying class
- ADS
- Underlying amount
- 121,212
- Exercise price
- $12.38
- Footnotes
- F4, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
These Ordinary Shares are held through 93,460 American Depositary Shares ("ADS") of the Issuer. Each ADS represents 35 Ordinary Shares.
Footnote F2
The reporting persons are Stonepine Capital Management, LLC ("Stonepine"), Stonepine Capital, L.P. (the "Partnership"), Stonepine GP, LLC ("Stonepine GP") and Jon M. Plexico. Stonepine and Stonepine GP are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and Stonepine GP. The Partnership hold these securities directly for the benefit of its investors. Stonepine and Stonepine GP may be deemed to indirectly beneficially own them as the investment adviser and general partner of the Partnership. Mr. Plexico may be deemed to indirectly beneficially own them as the control person of Stonepine and Stonepine GP. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
Footnote F3
The pre-funded warrants are exercisable at any time and have no expiration date.
Footnote F4
Each ADS represents 35 Ordinary Shares.
Footnote F5
The Series H warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the Issuer's public announcement that the Issuer has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance.
Footnote F6
The Series H warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the Issuer's public announcement that the Issuer has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance.
Footnote F7
The Series J warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance.
Footnote F8
The Series K warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the public announcement of the Issuer's sale of a Priority Review Voucher (PRV) and (ii) five years from the date of issuance.
SEC remarks
Stonepine is filing this Form 3 for itself, the Partnership, Stonepine GP and Mr. Plexico. The filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934.